OncoMed Pharmaceuticals, Inc. (OMED) Reaches $2.03 After 8.00% Down Move; Innovative Solutions & Support (ISSC) Sentiment Is 1.83

February 15, 2018 - By Peter Mason

The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is a huge mover today! The stock decreased 1.93% or $0.04 during the last trading session, reaching $2.03. About 56,001 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since February 15, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.The move comes after 9 months negative chart setup for the $76.85M company. It was reported on Feb, 15 by Barchart.com. We have $1.87 PT which if reached, will make NASDAQ:OMED worth $6.15 million less.

Innovative Solutions and Support, Inc., a systems integrator, designs, makes, sells, and services flight guidance and cockpit display systems. The company has market cap of $53.72 million. It offers flat panel display systems that could replicate the display of analog or digital displays on one screen and could replace existing displays in legacy aircraft, as well as used for security monitoring on-board aircraft and as tactical workstations on military aircraft; flight management systems that complement the IS&S flat panel display system upgrade for commercial air transport aircraft; and integrated standby units, which incorporate the measurement and display of attitude, altitude, airspeed, and navigation data into a single standby/backup navigation instrument for military, commercial air transport, and corporate/general aviation applications. It has a 11.04 P/E ratio. The firm also provides digital air data computers, which calculate various air data parameters, such as altitude, airspeed, vertical speed, angle of attack, and other information derived from the measure of air pressure; integrated air data computers and display units that calculate and convey air data information; altitude displays, which convey aircraft altitude measurements; airspeed displays, which convey various types of airspeed measurements; and altitude alerters that allow pilots to select a desired cruising altitude and provide warnings to pilots when an unacceptable deviation occurs.

The stock decreased 1.85% or $0.06 during the last trading session, reaching $3.19. About 8,335 shares traded. Innovative Solutions and Support, Inc. (ISSC) has risen 34.91% since February 15, 2017 and is uptrending. It has outperformed by 18.21% the S&P500.

Wealthtrust Axiom Llc holds 2.1% of its portfolio in Innovative Solutions and Support, Inc. for 1.52 million shares. Teton Advisors Inc. owns 123,000 shares or 0.04% of their US portfolio. Moreover, Bridgeway Capital Management Inc has 0.01% invested in the company for 172,054 shares. The Pennsylvania-based Wharton Business Group Llc has invested 0.01% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 6,639 shares.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $76.85 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Since October 10, 2017, it had 0 insider purchases, and 5 selling transactions for $27,111 activity. 1,398 shares were sold by HASTINGS PAUL J, worth $5,931. Hager Alicia J. sold $5,295 worth of stock or 1,248 shares. $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) was sold by Patel Sunil. $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares were sold by Gurney Austin. 1,248 OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares with value of $5,295 were sold by Lewicki John A..

Investors sentiment increased to 0.71 in 2017 Q3. Its up 0.12, from 0.59 in 2017Q2. It increased, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported. Burt Wealth Advisors holds 0.02% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 7,519 shares. Iguana Healthcare Mngmt Limited Liability Corp has 350,000 shares for 0.88% of their portfolio. Vanguard Group Inc owns 1.03M shares for 0% of their portfolio. Barclays Pcl invested in 0% or 1,868 shares. 25,592 were reported by Hodges Cap Mngmt. Perceptive Advisors Ltd Liability Corporation holds 1.04M shares or 0.18% of its portfolio. Proshare Advsrs Ltd Limited Liability Company stated it has 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Connor Clark Lunn Inv Mngmt Ltd accumulated 69,900 shares. Alyeska Gp Limited Partnership owns 521,883 shares for 0.02% of their portfolio. Birchview Cap Lp invested in 0.07% or 28,689 shares. Manufacturers Life Insur The, Ontario – Canada-based fund reported 2,762 shares. Deutsche Bank Ag stated it has 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Meeder Asset Mngmt owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 1,346 shares. Morgan Stanley has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 36,055 shares. Blackrock has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 792,338 shares.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on March, 14. They expect $-0.31 earnings per share, up 55.71% or $0.39 from last year’s $-0.7 per share. After $-0.28 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.71% negative EPS growth.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. BMO Capital Markets downgraded it to “Market Perform” rating and $6 target in Tuesday, April 11 report. The rating was maintained by Jefferies on Tuesday, September 26 with “Buy”. As per Monday, April 18, the company rating was initiated by Cantor Fitzgerald. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. Mizuho maintained the stock with “Neutral” rating in Wednesday, January 6 report. The rating was maintained by Jefferies on Thursday, August 24 with “Buy”. The company was initiated on Tuesday, December 20 by SunTrust. The firm has “Buy” rating given on Tuesday, January 26 by Mizuho. The firm has “Buy” rating given on Thursday, September 22 by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, August 10 by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Mason

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: